Mark Patron, MD
Ophthalmology · Denver, CONPI 1215134176
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (42.0%), food and beverage and ownership interests — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by AbbVie at 44.1% of the total. Reporting peaked in 2020 at $750 and has fallen 74.5% since, to $191 in 2025.
Across 32 payments — averaging $55.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$786
- US Retina LLC$379
- Genentech USA, Inc.$248
- Novartis$145
- Astellas Pharma US Inc$108
- ABB Con-cise Optical Group LLC$65
- plus $53 from 3 others
What the payments were for
- Food & beverage$63235%
- Education$75042%
- Entertainment$231%
- Ownership interest$37921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 3 | $786 |
| US Retina LLC | 1 | $379 |
| Genentech USA, Inc. | 11 | $248 |
| Novartis | 9 | $145 |
| Astellas Pharma US Inc | 4 | $108 |
| ABB Con-cise Optical Group LLC | 1 | $65 |
| Optos, Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Alcon | 1 | $15 |
How this compares
$1,784 in reported general payments places this provider in the 60th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 29 | $326 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Denver
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael JansenDenver$95K
- Kingsley OkaforDenver$62K
- Curtis HagedornDenver$25K
- Michael SolomonDenver$12K
- Peter HovlandDenver$10K
- Matthew KrugerDenver$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.